

## Daftar Pustaka

- Abdelhamid, T.M., Gaber, A.A., Abdelfattah, R.M., Algamal, D.A., Hamdy, O., & Mohamed, G. (2024). The significance of concurrent MYC and BCL2 expression in Egyptian patients with diffuse large B-cell NHL. *Pathology-Research and Practice.*, 253, p.154973.
- Abdulla, M., Laszlo, S., Triumph, J., Hedström, G., Berglund, M., Enblad, G., *et al.* (2016). A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients. *Acta Oncologica.*, 55(9-10), pp.1126-1131.
- Abramson, J.S. (2020). Anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma. *Transfusion medicine reviews.*, 34(1), pp.29-33.
- Aggarwal A, Rafei H, Alakeel F, et al(2016);. *Outcome of patients with double-expressor lymphomas (DELs) treated with R-CHOP or R-EPOCH* [abstract 5396]. Abstract presented at: 58th ASH Annual Meeting and Exposition; December 3-6, San Diego, CA
- Ahmad A, Ghani FA, Jaafar J, Abdullah MA (2022).Identification of MYC/BCL2 Double-expressers Lymphomas in Diffuse Large B Cell Lymphoma Patients and Association with their Prognostic Parameters and Survival Rates: A Single Centre Experience. *Malaysian Journal of Medicine and Health Sciences.*18(SUPP21): 86-91.
- Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., *et al.* (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature.*, 403(6769), pp.503-511.
- Amen F, Horncastle D, Elderfield K, Banham AH, Bower M, Macdonald D, *et al.* 2007. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very prognostic subgroup of patients. *Histopathology* ;51(1):70-9.
- Akyurek, N., Uner, A., Benekli, M. and Barista, I. (2012), Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab<sup>‡</sup>. *Cancer*, 118: 4173-4183
- Bellas, C., García, D., Vicente, Y., Kilany, L., Abraira, V., Navarro, B., *et al.* (2014). Immunohistochemical and molecular characteristics with

- prognostic significance in diffuse large B-cell lymphoma. *PloS one.*, 9(6), p.e98169.
- Chan, A., & Dogan, A. (2019). Prognostic and predictive biomarkers in diffuse large B-cell lymphoma. *Surgical pathology clinics.*, 12(3), pp.699-707.
- Chen, Y., Chen, H., Chen, L., Zheng, X., Yang, X., Zheng, Z., *et al.* (2019). Immunohistochemical overexpression of BCL-2 protein predicts an inferior survival in patients with primary central nervous system diffuse large B-cell lymphoma. *Medicine.*, 98(45), p.e17827.
- Chiappella, A., Crombie, J., Guidetti, A., Vitolo, U., Armand, P., & Corradini, P. (2019). Are we ready to treat diffuse large b-cell and high-grade lymphoma according to major genetic subtypes?. *Hemasphere.*, 3(5), p.e284.
- Collinge, B., Ben-Neriah, S., Chong, L., Boyle, M., Jiang, A., Miyata-Takata., *et al.* (2021). The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. *Blood, The Journal of the American Society of Hematology.*, 137(16), pp.2196-2208.
- Dang, C.V. (2012). MYC on the path to cancer. *Cell.*, 149(1), pp.22-35.
- Dave, S.S., Fu, K., Wright, G.W., Lam, L.T., Kluin, P., Boerma, E.J., *et al.* (2006). Molecular diagnosis of Burkitt's lymphoma. *New England Journal of Medicine.*, 354(23), pp.2431-2442.
- Dwianingsih, E.K., Hardianti, M.S., Malueka, R.G., Iswar, R.R., Sutapa, S.A., Triningsih, F.X., *et al.* (2016). Histopathological features of lymphoma in Yogyakarta, Indonesia. *Asian Pacific Journal of Cancer Prevention.*, 17(9), pp.4213-4216.
- Ennishi, D., Mottok, A., Ben-Neriah, S., Shulha, H.P., Farinha, P., Chan, F.C., *et al.* (2017). Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. *Blood, The Journal of the American Society of Hematology.*, 129(20), pp.2760-2770.
- Evan, G.I., Christophorou, M., Lawlor, E.A., Ringshausen, I., Prescott, J., Dansen, T., *et al.* (2005), January. Oncogene-dependent tumor suppression: using the dark side of the force for cancer therapy. *In Cold Spring Harbor Symposia on Quantitative Biology* (Vol. 70, pp. 263-273). Cold Spring Harbor Laboratory Press.

- Flowers CR, Shenoy PJ, Borate U, et al (2013). Examining racial differences in diffuse large B-cell lymphoma presentation and survival. *Leuk Lymphoma*. 54(2):268-276.
- Gouveia, G.R., Siqueira, S.A.C., & Pereira, J. (2012). Pathophysiology and molecular aspects of diffuse large B-cell lymphoma. *Revista brasileira de hematologia e hemoterapia.*, 34, pp.447-451.
- Green, T.M., Young, K.H., Visco, C., Xu-Monette, Z.Y., Orazi, A., Go, R.S., Nielsen, O., et al. (2012). Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. American Society of Clinical Oncology (ASCO).
- Hashmi, A.A., Iftikhar, S.N., Nargus, G., Ahmed, O., Asghar, I.A., Shirazi, et al. 2021. Double-Expressor Phenotype (BCL-2/c-MYC Co-expression) of Diffuse Large B-Cell Lymphoma and Its Clinicopathological Correlation. *Cureus* 13(2): e13155.
- Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., et al. (2004). Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood.*, 103(1), pp.275-282.
- Herrera, A.F., Mei, M., Low, L., Kim, H.T., Griffin, G.K., Song, J.Y., et al. (2017). Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. *Journal of Clinical Oncology.*, 35(1), p.24.
- Hill, M.E., MacLennan, K.A., Cunningham, D.C., Vaughan Hudson, B., Burke, M., Clarke, P., et al. (1996). Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. *Blood.*, Aug 1;88(3):1046-51.
- Horn, H., Ziepert, M., Becher, C., Barth, T.F., Bernd, H.W., Feller, A.C., et al. (2013). MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. *Blood, The Journal of the American Society of Hematology.*, 121(12), pp.2253-2263.
- Hu, S., Xu-Monette, Z.Y., Tzankov, A., et al. (2013) MYC/BCL2 double-expressor lymphoma identified by immunohistochemistry exhibits poor prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program Study, *Blood*, 121(20), pp. 4021–4031

- Huang, H., Fan, L., Fu, D., Lin, Q., & Shen, J. (2020). Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center. *Annals of Palliative Medicine.*, 9(4), pp.1442452-1441452.
- Hwang, J., Suh, C.H., Kim, K.W., Kim, H.S., Kim, A.I., Craig, J.W., *et al.* (2021). The incidence and treatment response of double expression of MYC and BCL2 in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. *Cancers.*, 13(13), p.3369.
- Istiadi, H., Sadhana, U., Puspasari, D., Miranti, I.P., Karlowee, V., Listiana, D.E., Prasetyo, A. (2021) Prognostic significance of double expressor lymphoma subtype in patient with diffuse large B-cell lymphoma. *Bali Medical Journal*, 10(1), pp. 366-372.
- Iqbal J, Vishala T. Neppalli, Wright G, Bhavana J. Dave, Douglas E. Horsman, Rosenwald A, *et al.*, (2006). *BCL2* Expression Is a Prognostic Marker for the Activated B-Cell-Like Type of Diffuse Large B-Cell Lymphoma . *JCO* 24, 961-968.
- Johnson, N.A., Slack, G.W., Savage, K.J., Connors, J.M., Ben-Neriah, S., Rogic, S., *et al.* (2012). Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. *Journal of clinical oncology.*, 30(28), p.3452.
- Jung, M., Russell, A.J., Liu, B., George, J., Liu, P.Y., Liu, T., *et al.* (2017). A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers. *Cancer research.*, 77(4), pp.971-981.
- Karube, K., & Campo, E. (2015). MYC alterations in diffuse large B-cell lymphomas. *In Seminars in hematology* (Vol. 52, No. 2, pp. 97-106). WB Saunders.
- Kim, J.S., Liu, Y., Ha, K.H., Qiu, H., Rothwell, L.A., Kim, H.C., *et al.* (2020). Increasing incidence of B-cell non-Hodgkin lymphoma and occurrence of second primary malignancies in South Korea: 10-year follow-up using the Korean National Health Information database. *Cancer Research and Treatment: Official Journal of Korean Cancer Association.*, 52(4), p.1262.
- Kluk, M.J., Chapuy, B., Sinha, P., Roy, A., Cin, P.D., Neuberg, D.S., *et al.* (2012). Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. *PloS one.*, 7(4), p.e33813.
- Li, L, Li, Y, Que, X, Gao, X, Gao, Q, Yu, M, *et al.* 2018. Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-

treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis. *Sci. Rep.* 8, 6267.

Li, S., Lin, P., Young, K.H., Kanagal-Shamanna, R., Yin, C.C., Medeiros, L.J., *et al.* (2013). MYC/BCL2 double-hit high-grade B-cell lymphoma. *Advances in anatomic pathology.*, 20(5), pp.315-326.

Li Y, Wang Y, Wang Z, Yi D, Ma S (2015) Racial differences in three major NHL subtypes: descriptive epidemiology. *Cancer Epidemiol.*39(1):8-13.

Lossos, I.S. (2005). Molecular pathogenesis of diffuse large B-cell lymphoma. *Journal of Clinical Oncology.*, 23(26), pp.6351-6357.

McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med (Zagreb)*. 2012;22(3):276-82

Melchardt, T., Egle, A., & Greil, R. (2023). How I treat diffuse large B-cell lymphoma. *ESMO open.*, 8(1), p.100750.

Miura, K., Takahashi, H., Nakagawa, M., Izu, A., Sugitani, M., Kurita, D., *et al.* (2016). Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy. *Leukemia & lymphoma.*, 57(6), pp.1335-1341.

Miyamoto, K.I., Kobayashi, Y., Maeshima, A.M., Taniguchi, H., Nomoto, J., Kitahara, H., *et al.* (2016). Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. *International Journal of Hematology.*, 103, pp.693-702.

Nguyen, L., Papenhausen, P., & Shao, H., *et al.* (2017). The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects. *Genes.*, 8(4), p.116.

Nowakowski, G.S., Blum, K.A., Kahl, B.S., Friedberg, J.W., Baizer, L., Little, R.F., *et al.* (2016). Beyond RCHOP: a blueprint for diffuse large B cell lymphoma research. *JNCI: Journal of the National Cancer Institute.*, 108(12), p.djw257.

Ott, G., Rosenwald, A., & Campo, E. (2013). Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. *Blood, The Journal of the American Society of Hematology.*, 122(24), pp.3884-3891.

Perry, A. M., Alvarado-Bernal, Y., Laurini, J. A., Smith, L. M., Slack, G. W., Tan, K. L., Sehn, L. H., Fu, K., Aoun, P., Greiner, T. C., Chan, W. C., Bierman, P. J., Bociek, R. G., Armitage, J. O., Vose, J. M., Gascoyne, R. D., & Weisenburger, D. D. (2013). MYC and BCL2 protein expression

predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. *Hematological Oncology*, 31(4), 215-222.

Poeschel, V., Held, G., Ziepert, M., Witzens-Harig, M., Holte, H., Thurner, L., *et al.* (2019). Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. *The Lancet.*, 394(10216), pp.2271-2281.

Punnoose, E., Peale, F.V., Szafer-Glusman, E., Lei, G., Bourgon, R., Do, A.D., *et al.* (2021). BCL2 expression in first-line diffuse large B-cell lymphoma identifies a patient population with poor prognosis. *Clinical Lymphoma Myeloma and Leukemia.*, 21(4), pp.267-278.

Riedell, P.A., & Smith, S.M. (2018). Double hit and double expressors in lymphoma: definition and treatment. *Cancer.*, 124(24), pp.4622-4632.

Ratast, A.S., Dixon, J.G., Salles, G., Wall, A., Cunningham, D., Poeschel, V., *et al.* (2020). International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. *Blood, The Journal of the American Society of Hematology.*, 135(23), pp.2041-2048.

Sarkozy, C., & Coiffier, B. (2013). Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties. *Clinical Cancer Research.*, 19(7), pp.1660-1669.

Sarkozy, C., Traverse-Glehen, A., & Coiffier, B. (2015). Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. *The Lancet Oncology*, 16(15), pp.e555-e567.

Sasaki, Y., Hattori, N., Uesugi, Y., Nakata, A., Shimada, S., Watanuki, M., *et al.* (2021). Evaluation of MYC protein expression using immunohistochemistry in extranodal Diffuse large B-cell lymphoma. *昭和学会雑誌 (Web.)*, 81(4), pp.306-315.

Savage, K.J., Johnson, N.A., Ben-Neriah, S., *et al.* (2009) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy, *Blood*, 114(17), pp. 3533–3537.

Sebastian, N., Ananthkrishnan, R., Kumanan, J., Chandran, C., & Raja, T. (2024). Molecular Profiling of High-Grade B-Cell Non-Hodgkin Lymphomas and Its Clinicopathologic Correlation in an Indian Tertiary Cancer Care Center. *Indian Journal of Medical and Paediatric Oncology.*

- Shi, Y., Han, Y., Yang, J., Liu, P., He, X., Zhang, C., *et al.* 2019. Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China. *Chinese journal of cancer research.*, 31(1), p.152.
- Su, F. and Lian, K. 2023. Prognostic evaluation of system immune-inflammatory index and prognostic nutritional index in double expressor diffuse large B-cell lymphoma. *Open Medicine*, Vol. 18 (Issue 1), pp. 20230819
- Sweetenham, J.W. (2007). Diffuse Large B-Cell Lymphoma. *Lymphoma: Pathology, Diagnosis and Treatment.*, p.168.
- Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., *et al.* (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood, The Journal of the American Society of Hematology.*, 127(20), pp.2375-2390.
- Teoh, C.S., Lee, S.Y., Chiang, S.K., Chew, T.K., & Goh, A.S. (2018). Impact of double expression of C-MYC/BCL2 protein and cell of origin subtypes on the outcome among patients with diffuse large B-cell lymphoma: a single Asian center experience. *Asian Pacific journal of cancer prevention: APJCP.*, 19(5), p.1229.
- Ting, C.Y., Chang, K.M., Kuan, J.W., Sathar, J., Chew, L.P., Wong, O.L.J., *et al.* (2019). Clinical significance of BCL2, C-MYC, and BCL6 genetic abnormalities, Epstein-Barr virus infection, CD5 protein expression, germinal center B cell/non-germinal center B-cell subtypes, co-expression of MYC/BCL2 proteins and co-expression of MYC/BCL2/BCL6 proteins in diffuse large B-cell lymphoma: a clinical and pathological correlation study of 120 patients. *International Journal of Medical Sciences.*, 16(4), p.556.
- Tomas-Roca, L., Rodriguez, M., Alonso-Alonso, R., Rodriguez-Pinilla, S.M., & Piris, M.A. (2021). Diffuse large B-cell lymphoma: recognition of markers for targeted therapy. *Hemato.*, 2(2), pp.281-304.
- Tsuyama N, Sakata S, Baba S, Mishima Y, Nishimura N, Ueda K, Yokoyama M, Terui Y, Hatake K, Kitagawa M, Ishizuka N, Tomita N, Takeuchi K. 2017.BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. *Blood*. Jul 27;130(4):489-500.
- Utomo, D.I., Ham, M.F., Kusmardi, K., & Hardjolukito, E.S. (2018). Perbedaan Ekspresi BCL-2 pada Limfoma Sel B Jenis Sel Besar Difus sebagai Salah

Satu Petanda Subtipe Germinal Center B-Cell Like dan Non-Germinal Center B-Cell Like. *Majalah Patologi Indonesia.*, 27(1), pp.18-23.

Wu, G., & Keating, A. (2006). Biomarkers of potential prognostic significance in diffuse large B- cell lymphoma. *Cancer: Interdisciplinary International Journal of the American Cancer Society*, 106(2), pp.247-257.

Xavier Fa ,Levy D, Pereira J. (2014). Time-to-treatment of DLBCL in Sa o Paulo. *CLINICS.*,69(5):367-371.

Xia, Y., & Zhang, X. (2020). The spectrum of MYC alterations in diffuse large B-cell lymphoma. *Acta haematologica.*, 143(6), pp.520-528.

Zhang Y, Wang H, Ren C, Yu H, Fang W, Zhang N, Gao S, Hou Q. 2019. Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma. *Front Pharmacol.* Jan 7;9:1497.

Zimmermann C, Burman D, Bandukwala S, Seccareccia D, Kaya E, Bryson J, et al. (2010). Nurse and physician inter-rater agreement of three performance status measures in palliative care outpatients. *Support Care Cancer.* May;18((5)):609–16.